Hann-Hsiang Chao

Dr. Hann-Hsiang Chao

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
JLJose Marcio Luna
Jose Marcio Luna
HCHann-Hsiang Chao
Hann-Hsiang Chao
EDEric S. Diffenderfer
Eric S. Diffenderfer
GVGilmer Valdes
Gilmer Valdes
CCChidambaram Chinniah
Chidambaram Chinniah
CSCharles Simone
Charles Simone

1 November 2019 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
AGAmardeep S. Grewal
Amardeep S. Grewal
CSCaitlin Schonewolf
Caitlin Schonewolf
EMEun Jeong Min
Eun Jeong Min
HCHann-Hsiang Chao
Hann-Hsiang Chao
SBStefan Both
Stefan Both
NVNeha Vapiwala
Neha Vapiwala

16 February 2023 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
MMMarni B. McClure
Marni B. McClure
YKYasunori Kogure
Yasunori Kogure
NANaser Ansari-Pour
Naser Ansari-Pour
YSYuki Saito
Yuki Saito
HCHann-Hsiang Chao
Hann-Hsiang Chao
KKKeisuke Kataoka
Keisuke Kataoka
The hallmark signatures based on gene expression capture core cancer processes. Through a pan-cancer analysis, we describe the overview of hallmark signatures across tumor types/subtypes and reveal significant relationships between these signatures and genetic alterations. TP53 mutation exerts diverse changes, including increased proliferation and glycolysis, which are closely mimicked by widespread copy-number alterations. Hallmark signature and copy-number clustering identify a cluster of squamous tumors and basal-like breast and bladder cancers with elevated proliferation signatures, frequent TP53 mutation, and high aneuploidy. In these basal-like/squamous TP53-mutated tumors, a specific and consistent spectrum of copy-number alterations is preferentially selected prior to whole-genome duplication. Within Trp53-null breast cancer mouse models, these copy-number alterations spontaneously occur and recapitulate the hallmark signature changes observed in the human condition. Together, our analysis reveals intertumor and intratumor heterogeneity of the hallmark signatures, uncovering an oncogenic program induced by TP53 mutation and select aneuploidy events to drive a worsened prognosis.Significance: Our data demonstrate that TP53 mutation and a resultant selected pattern of aneuploidies cause an aggressive transcriptional program including upregulation of glycolysis signature with prognostic implications. Importantly, basal-like breast cancer demonstrates genetic and/or phenotypic changes closely related to squamous tumors including 5q deletion that reveal alterations that could offer therapeutic options across tumor types regardless of tissue of origin.

14 August 2019 in Head & Neck
Verified
Journal Article
Closed access
PDF file
HCHann-Hsiang Chao
Hann-Hsiang Chao
CSCaitlin A. Schonewolf
Caitlin A. Schonewolf
ETErik X. Tan
Erik X. Tan
SSSamuel Swisher‐McClure
Samuel Swisher‐McClure
AGAlireza F. Ghiam
Alireza F. Ghiam
JLJohn N. Lukens
John N. Lukens

15 October 2019 in British Journal of Radiology
Verified
Journal Article
Closed access
JGJared Gershowitz
Jared Gershowitz
HCHann-Hsiang Chao
Hann-Hsiang Chao
ADAbigail Doucette
Abigail Doucette
JLJohn N Lukens
John N Lukens
SSSamuel Swisher-McClure
Samuel Swisher-McClure
ALAlexander Lin
Alexander Lin
Objective: One approach to reduce treatment-related morbidity for human papilloma virus (HPV)-associated tonsil cancer is omitting radiotherapy to the contralateral neck. Pathologic risk factors for early contralateral neck disease, however, are poorly understood. We report on the risk contralateral neck failures from the time of pre-operative diagnostic imaging to time of planning for adjuvant radiation in a single institution series of HPV-associated tonsillar cancer patients undergoing surgery followed by radiotherapy (RT). Methods: Retrospective analysis of 123 patients with T1–T3 HPV-positive tonsillar squamous cell carcinoma treated between 2010 and 2016 with transoral robotic surgery and selective ipsilateral neck dissection followed by adjuvant RT. Contralateral neck recurrence was classified as the detection of a pathologic node in the contralateral neck prior to initiation of adjuvant RT. Results: Seven patients (5.7%) developed contralateral neck disease/failure between the time of pre-operative diagnostic neck imaging and time of planning of adjuvant radiation. Increased ratio of positive/resected nodes [odds ratio (OR) 1.073, p = 0.005] was significantly associated with increased risk of contralateral neck recurrence, with a trend found for close/positive margins (OR 5.355, p = 0.06), tumor size (OR 2.046, p = 0.09), and total number of nodes positive (OR 1.179, p = 0.062). Conclusions: Patients who develop very early contralateral neck disease, between completion of ipsilateral neck dissection and the initiation of radiotherapy, have a higher ratio of positive nodes to total nodes resected in the ipsilateral neck. These findings suggest that proper selection of patients for omission of treatment of the contralateral, node-negative neck should be made with this in mind, with future studies needed to document the impact on toxicity and disease outcomes from such an approach. Advances in knowledge: Pathologic risk factors in the dissected, ipsilateral neck in patients with tonsil cancer may inform the risk of contralateral neck failure. Patient selection for future, prospective efforts to examine sparing of the contralateral neck need to be based with these risk factors in mind.

15 March 2022 in Cancer Medicine
Verified
Journal Article
Open access
HCHann-Hsiang Chao
Hann-Hsiang Chao
PSPayal D. Soni
Payal D. Soni
BDBassam Dahman
Bassam Dahman
SSSpiro C. Stilianoudakis
Spiro C. Stilianoudakis
HFHampton Ford
Hampton Ford
MCMichael G. Chang
Michael G. Chang
Background: The optimal upfront treatment modality for patients with nonmetastatic Gleason Score 9 and 10 prostate cancer (GS 9–10 PCa) is unknown.Methods: We conducted a retrospective cohort study of patients in the Veterans Health Administration (VHA) with GS 9–10 PCa treated with radical prostatectomy (RP) or external beam radiation therapy with androgen deprivation therapy (EBRT+ADT) from 1/2000 to 12/2010. Outcomes included overall survival (OS), distant metastasis‐free survival (DMFS), and salvage/adjuvant therapy‐free survival (SAFS), as assessed by Kaplan–Meier analysis.Results: We identified 1220 veterans with GS 9–10 PCa; 335 were treated with RP, and 885 were treated with EBRT+ADT. With a median follow‐up of 9.9 years, propensity score‐matched analyses demonstrated that RP had superior 10‐year OS (70.8% [RP] vs. 61.2% [EBRT+ADT], p < 0.001), 10‐year DMFS rates were similar between RP (76.7%) and EBRT+ADT (81.0%), and 10‐year SAFS rates were lower for RP vs EBRT + ADT (35.2% [RP] vs. 75.2% [EBRT+ADT], p < 0.001). The receipt of salvage ADT was higher with upfront RP (51.9% vs. 26.1%, p < 0.001), despite receipt of adjuvant/salvage EBRT in 41.8% of RP patients. Among patients treated with RP, there were no differences in outcomes by race. However, higher survival rates were noted among Black patients treated with EBRT+ADT compared with White patients.Conclusions: This analysis demonstrated higher 10‐year OS rates among men treated with upfront RP versus EBRT+ADT, though missing confounders and similar DMFS rates suggest the long‐term cause‐specific OS rates may be similar. We also highlight real‐world outcomes of a diverse patient population in the VHA and improved outcomes for Black patients receiving EBRT+ADT.